Oncotelic Therapeutics, Inc.
OTLC
$0.03
$0.001.00%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1,961.36% | 1,426.60% | 693.14% | 54.71% | -30.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1,963.92% | 1,428.71% | 694.12% | 50.53% | -35.44% |
| Operating Income | -1,874.45% | -1,428.71% | -694.12% | -50.53% | 22.99% |
| Income Before Tax | 8,684.25% | 7,783.08% | 7,644.04% | 60.89% | -178.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 6,015.66% | 5,393.76% | 5,310.16% | 60.89% | -178.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -15.38% | -7.70% | -0.23% | -1.44% | -3.98% |
| Net Income | 6,403.68% | 5,704.68% | 5,610.29% | 64.17% | -216.83% |
| EBIT | -1,874.45% | -1,428.71% | -694.12% | -50.53% | 22.99% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 5,942.71% | 5,291.67% | 5,189.19% | 65.81% | -190.91% |
| Normalized Basic EPS | -911.11% | -323.53% | -164.71% | -43.75% | 18.18% |
| EPS Diluted | 5,881.44% | 5,290.74% | 5,188.29% | 64.96% | -193.94% |
| Normalized Diluted EPS | -800.00% | -329.41% | -170.59% | -50.00% | 9.09% |
| Average Basic Shares Outstanding | 7.89% | 5.92% | 4.20% | 5.81% | 5.23% |
| Average Diluted Shares Outstanding | 6.24% | 8.66% | 6.95% | 8.67% | 8.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |